Central retinal vein occlusion, also known as CRVO, is a condition in which the main vein that drains blood from the retina closes off partially or completely. This can cause blurred vision and other problems with the eye.
DelveInsight’s “Central Retinal Vein Occlusion Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Central Retinal Vein Occlusion, historical and forecasted epidemiology as well as the Central Retinal Vein Occlusion market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some Key Highlights from the Central Retinal Vein Occlusion Market Report:
- In the 7MM, the total diagnosed cases of Retinal Vein Occlusion by age distribution were 1,166,736, 535,472, and 318,025 cases for the age group less than 65 years, 65-74 years, and ≥75 years, in 2020.
- According to DelveInsight, the majority of cases of Retinal Vein Occlusion are found in females as compared to males.
- In the 7MM, Central retinal vein occlusion contributed to 407,058 cases in 2020. Furthermore, in 2020, there were around 1,613,175 BRVO cases.
- US has the highest percentage of prevalent, diagnosed and treated patients.
- The Retinal Vein Occlusion Market size was found to be USD 2,328 Million in 2020 in 7MM.
View Report: https://www.delveinsight.com/report-store/central-retinal-vein-occlusion-market
Request for Sample Report @ https://www.delveinsight.com/sample-report/central-retinal-vein-occlusion-market
Mild Central retinal vein occlusion may show no symptoms. However:
- Many patients with Central retinal vein occlusion have symptoms such as blurry or distorted vision due to swelling of the center part of the retina, known as the macula.
- Some patients have mild symptoms that wax and wane, called transient visual obscurations.
- Patients with severe Central retinal vein occlusion and secondary complications such as glaucoma (a disease characterized by increased pressure in the eye) often have pain, redness, irritation and other problems.
View Report: https://www.delveinsight.com/report-store/central-retinal-vein-occlusion-market
Request for Sample Report @ https://www.delveinsight.com/sample-report/central-retinal-vein-occlusion-market
Some of the Central Retinal Vein Occlusion Companies:
- Regeneron Pharmaceuticals
- Bayer
- The Emmes Company, LLC
- Novartis
- Genentech, Inc
- Bausch & Lomb
- And Many More
View Report: https://www.delveinsight.com/report-store/central-retinal-vein-occlusion-market
Request for Sample Report @ https://www.delveinsight.com/sample-report/central-retinal-vein-occlusion-market
Central Retinal Vein Occlusion Pipeline Therapies:
- Sham
- Brolucizumab
- Aflibercept
- Bevacizumab
- Aflibercept
- BAY86-5321
- Ranibizumab
- And Many Others
Table of Contents
| 1. | Report Introduction |
| 2. | Executive Summary of Central Retinal Vein Occlusion |
| 3. | Central Retinal Vein Occlusion Market Overview at a Glance |
| 4. | Disease Background and Overview: Central Retinal Vein Occlusion |
| 5. | Case Reports of Central Retinal Vein Occlusion |
| 6. | Central Retinal Vein Occlusion Patient Journey |
| 7. | Central Retinal Vein Occlusion Epidemiology and Patient Population |
| 8. | Epidemiology of Central Retinal Vein Occlusion by Countries (2018–2030) |
| 9. | Central Retinal Vein Occlusion Treatments and Medical Practices |
| 10. | Central Retinal Vein Occlusion Marketed Therapies |
| 11. | Central Retinal Vein Occlusion Emerging Therapies |
| 12. | Central Retinal Vein Occlusion Market Size |
| 13. | 7MM: Country-wise Market Analysis |
| 14. | Central Retinal Vein Occlusion Market Drivers |
| 15. | Central Retinal Vein Occlusion Market Barriers |
| 16. | SWOT Analysis |
| 17. | KOL Views |
| 18. | Reimbursement and market access |
| 19. | Report Methodology |
| 20. | DelveInsight Capabilities |
| 21. | Disclaimer |
| 22. | About DelveInsight |
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.